Press coverage about Zoetis (NYSE:ZTS) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Zoetis earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.496166511981 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Technical Facts to Know Zoetis Inc. (ZTS) moves 61.44% away from One Year Low – Nasdaq Chronicle (nasdaqchronicle.com)
- Ferris Capital LLC Invests $356000 in Zoetis Inc (ZTS) Stock (ontariocanews.com)
- As Zoetis INC (ZTS) Shares Rose, Shareholder Johnson Investment Counsel INC Trimmed by $3.17 Million Its Holding – The Louisville Oracle (louisvilleoracle.com)
- Zoetis Inc. (ZTS) projected to achieve 32.40% earnings growth for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Roman Trawicki Sells 8,568 Shares of Zoetis Inc (ZTS) Stock (americanbankingnews.com)
ZTS stock traded down $0.09 during midday trading on Friday, reaching $84.60. The company had a trading volume of 2,669,216 shares, compared to its average volume of 2,393,871. Zoetis has a fifty-two week low of $52.25 and a fifty-two week high of $85.54. The firm has a market capitalization of $41,052.49, a PE ratio of 48.34, a P/E/G ratio of 1.90 and a beta of 0.97. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a $0.126 dividend. The ex-dividend date is Thursday, April 19th. This represents a $0.50 annualized dividend and a yield of 0.60%. Zoetis’s payout ratio is currently 28.57%.
Several analysts recently weighed in on ZTS shares. UBS restated a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Morgan Stanley upgraded Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective for the company in a research report on Wednesday, November 29th. Cantor Fitzgerald set a $80.00 price objective on Zoetis and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Craig Hallum restated a “buy” rating and set a $85.00 price objective (up from $77.00) on shares of Zoetis in a research report on Tuesday, January 2nd. Finally, Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $80.28.
In other Zoetis news, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the transaction, the executive vice president now owns 49,919 shares in the company, valued at $4,044,437.38. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Heidi C. Chen sold 37,453 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,569 shares of company stock worth $8,594,429. Corporate insiders own 0.31% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zoetis (ZTS) Given Daily News Sentiment Rating of 0.14” was first reported by BBNS and is owned by of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/03/18/zoetis-zts-getting-somewhat-positive-press-coverage-report-finds/2012220.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.